Digest Network Come funziona
Network
/
Società
Br
Non verificato

Bristol Myers Squibb

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

133 comunicati stampa

Guarda tutti i comunicati
30/04/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Chimica
Industria
Scienza
Farmaceutica
Biotecnologia
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
24/04/2026
Mercato del lavoro
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
31/03/2026
Analisi di mercato
Industria
Sanità
Associazioni/Professionisti
Cardiologia
Management
Biotecnologia
Salute
Farmaceutica
Oncologia
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
29/03/2026
Eventi
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
28/03/2026
Eventi
Fiere
Industria
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
23/03/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Eventi
Industria
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
20/03/2026
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
19/03/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Scienza
Farmaceutica
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
09/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
07/03/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0